Elodie Sadowski

Elodie Sadowski

Auto-generated profile, based on publicly available information

Elodie Sadowski

AP-HP, Hôpital Pitié-Salpêtrière, Service da bactériologie, Centre National de Référence des mycobactéries et de la résistance des mycobactéries aux antituberculeux, F-75013 Paris, France

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
DKDaniel Krentzel
Daniel Krentzel
JPJulienne Petit
Julienne Petit
YBYves-Marie Boudehen
Yves-Marie Boudehen
NMNassim Mahtal
Nassim Mahtal
ESElodie Sadowski
Elodie Sadowski
AWAnne Marie Wehenkel
Anne Marie Wehenkel
Tuberculosis (TB) is the worldwide leading infectious killer due to a single pathogen and increasing antimicrobial resistance (AMR) makes it imperative to discover and develop new drugs with novel modes of action (MoAs) to treat TB infections. Phenotypic screening of chemical libraries has proven effective at identifying new compounds against bacterial pathogens. However, a major limitation of standard screens is their inability to uncover the MoA of hits thereby preventing targeted selection of compounds with novel MoAs. Linking drug perturbations to mutants from images could potentially enable to predict the targets of compounds that act through novel MoAs. Here, we develop a deep learning (DL)-based method to screen drug-treated Corynebacterium glutamicum ( Cglu ), a surrogate model for Mycobacterium tuberculosis ( Mtb ). Our DL model is based on a convolutional neural network architecture that takes high throughput images as input and is trained to distinguish between different MoAs. We show that our approach can robustly differentiate between the MoAs of established antibiotics and correctly recognise the MoA of antibiotics that were not previously seen by the DL model. We also show that inhibitors with the same and previously unseen MoA cluster together and apart from all other reference drugs, allowing for new MoA discovery. Importantly, we show that our model links images of chemical (drugs) and genetic (mutants) perturbations targeting similar pathways, thus paving the way towards mutant-based target prediction of compounds that act through novel MoAs, directly from high-content images. Finally, we explore the phenotypes induced by genetic disruption of pathways and demonstrate that features extracted with our DL model recover known biological relationships from high-throughput images alone using the cell cycle of Cglu as a case study, a finding with promising potential for fundamental mechanistic studies.

11 July 2026
Verified
Dataset
Closed access
DKDaniel Krentzel
Daniel Krentzel
JPJulienne Petit
Julienne Petit
YBYves-Marie Boudehen
Yves-Marie Boudehen
NMNassim Mahtal
Nassim Mahtal
ESElodie Sadowski
Elodie Sadowski
AWAnne Marie Wehenkel
Anne Marie Wehenkel
BioStudies – one package for all the data supporting a study